Navigation Links
Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
Date:2/6/2008

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, planned clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
2. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
3. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
4. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
5. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
7. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
8. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
10. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
11. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Calif. (PRWEB) January 15, 2014 Cynvenio, ... and management through the genomic analysis of tumor cells ... Therapy Finder™, a web-based cancer decision support application powered ... option with Cynvenio’s ClearID™ genomic test, Therapy Finder will ...
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... March 20, 2012 /PRNewswire-iReach/ -- Systems Alliance, ... build, assess and optimize online properties, today announced it ... The Living Legacy Foundation . The non-profit organization facilitates ... for transplantation and research in Maryland with the exception ...
... FULTON, Miss., March 20, 2012  Frank A. Critz, M.D., founder ... honored with a hometown hero,s welcome this April when he ... prostate cancer survivors.  The event will be April 14, 2012 ... Street in Fulton from noon until 3 p.m., and lunch ...
... 2012 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an ... fight Human Immunodeficiency Virus (HIV) infections, announced today ... certain institutional investors, pursuant to which the Company ... A convertible preferred stock at an aggregate purchase ...
Cached Biology Technology:Systems Alliance Launches Redesigned Website for The Living Legacy Foundation of Maryland 2Systems Alliance Launches Redesigned Website for The Living Legacy Foundation of Maryland 3Radiotherapy Clinics of Georgia's Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award 2GeoVax Announces Private Placement of $2.2 Million 2GeoVax Announces Private Placement of $2.2 Million 3GeoVax Announces Private Placement of $2.2 Million 4
(Date:7/9/2014)... some shark species may be able to cope with the ... temperatures. , The Arctic today is best known for its ... that. Roughly 53 to 38 million years ago during what ... similar to a huge temperate forest with brackish water, home ... hippo-like creatures, crocodiles and giant tortoises. Much of what is ...
(Date:7/9/2014)... The U.S. may be on the verge of an economy ... burns cleaner than coal and is undergoing a production boom. ... globally, but recent research is casting serious doubts over just ... Chemical & Engineering News (C&EN), the weekly news magazine ... Johnson, a senior correspondent at C&EN, explains that when burned ...
(Date:7/9/2014)... can alleviate the symptoms of Alzheimer,s disease, ... and effectively scavenge amyloid beta peptide in ... reduced and eliminated Aβ deposition in an ... significantly improved behavioral and cognitive impairment. Dr. ... Hospital of China Medical University, China immunized ...
Breaking Biology News(10 mins):Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... -- The Society of Environmental Toxicology and Chemistry will present ... its 33rd Annual Meeting, November 11 at the Long Beach ... the Rosenstiel School of Marine & Atmospheric Science of the ... to the understanding of fate and effects of metals in ...
... Four young scientists have received postdoctoral fellowships from the ... program, they conduct research with the eventual aim of ... receiving mentorship from a faculty member at their home ... seven research teams. This allows them to interact with ...
... 2012  Verinata Health, Inc., a privately-held company dedicated to ... at the 62 nd Annual Meeting of the ... being held in San Francisco, California. (Logo: ... offers pregnant women access to a blood test that ...
Cached Biology News:SETAC announces Chris Lee Award for metals research winner, Kevin Brix 2Space research institute awards postdoctoral fellowships to 4 scientists 2Verinata Health Announces New Findings At The American Society Of Human Genetics 2
SDS-OutT SDS Precipitation Reagent...
... for fully automated systems for a broad ... configured for applications ranging from compound logistics, ... loop screening, which means it has fully ... picking and follow up studies all at ...
... Series of systems provide fast and reliable scalable automation ... development laboratories. Staccato systems are available in three base ... Series. ... All Staccato Application ...
Comp Dim: chamber L W D 45 45 0.8 mm chamber maximum volume 1500 μL...
Biology Products: